SCHEMBL420399

SCHEMBL420399

CCOC(=O)c1cc(-c2ccc(F)c(Cl)c2)c(-c2cc(F)cc(C#N)c2)s1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 1/20 0.51
PGR P06401 1/20 0.39
PTPRC P08575 1/20 0.38
PTPN2 P17706 1/20 0.38
PTPN1 P18031 1/20 0.38
PTPA Q15257 1/20 0.38
CHRM3 P20309 5/20 0.37
CHRM2 P08172 1/20 0.37
CHRM1 P11229 1/20 0.37
KDM4E B2RXH2 3/20 0.36
ALDH1A1 P00352 2/20 0.36
HPGD P15428 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
PTGS1 P23219 1/20 0.36
PTGS2 P35354 1/20 0.36
FNTA P49354 3/20 0.35
FNTB P49356 3/20 0.35
OPRD1 P41143 1/20 0.34
NPC1 O15118 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL421904 0.88 MAPK14 (0.56) MAPK14PTPRCPTPN2PTPN1PTPA
SCHEMBL2510401 0.85 PGR (0.40) MAPK14PGRPTPRCPTPN2PTPN1
SCHEMBL421510 0.85 MAPK14 (0.45) MAPK14
SCHEMBL422503 0.85 MAPK14 (0.48) MAPK14KDM4EALDH1A1HPGDTDP1
SCHEMBL423848 0.84 MAPK14 (0.52) MAPK14KDM4EALDH1A1HPGDTDP1
SCHEMBL423834 0.79 MAPK14 (0.43) MAPK14PGRPTPN2KDM4EALDH1A1
SCHEMBL14735844 0.79 XDH (0.35) PGRCHRM3CHRM2CHRM1PTGS2
SCHEMBL418491 0.78 PGR (0.41) PGRPTPRCPTPN2PTPN1PTPA
SCHEMBL426748 0.77 FNTA (0.47) MAPK14KDM4EALDH1A1HPGDTDP1
SCHEMBL422505 0.75 MAPK14 (0.41) MAPK14PGRCHRM3CHRM2CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546438-B2 Substituted (thiophenyl-carbonyl)imidazolidinones, and use thereof BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2013-10-01 US disclosed
US-20120022123-A1 SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022123-A1 SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF TPMT, MAVS, EIF2AK2 MAPK14 2294/4885PGR 2778/4885PTPRC 102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.